Lopez LR, Miller CM, Jeyachandran JN, Li C, Simpson KW, Arthur JC. Heterogeneity among clinical intestinal escherichia coli isolates upon acquired streptomycin resistance. Microbiol Spectr. 2023 Jun 15;11(3):e035022. doi: 10.1128/spectrum.03500-22
McLauchlan L, Lancaster K, Kearnes M, Mellor R, Ritter A. "It's professional but it's personal": participation, personal connection, and sustained disagreement in drug policy reform. Int J Drug Policy. 2022 Dec;110:103903. doi: 10.1016/j.drugpo.2022.103903
Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch DA. Erratum for Earnshaw et al., Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Oct 26;10(5):e0303122. doi: 10.1128/spectrum.03031-22
Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22
Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017 May;43:83-90. doi: 10.1016/j.drugpo.2017.01.018.
Kosa KM, Giombi KC, Rains CB, Cates SC. Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington. Int J Drug Policy. 2017 May;43:57-66. doi: 10.1016/j.drugpo.2017.01.006
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease evidence from a United States managed care population. Hum Vacci. 2011 Apr 1;7(4):458-65.
Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vacci. 2011 Jan 1;7(1):96-101.